Ezetimibe therapy for dyslipidemia: An update

Current Pharmaceutical Design

Volumn 19, Issue 17, 2013, Pages 3107-3114

  Katsiki, Niki ^a   Theocharidou, Eleni ^a   Karagiannis, Asterios ^a   Athyros, Vasilios G ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cholesterol; Clinical trials; Drug combinations; Dyslipidemia; Ezetimibe; Pleiotropic actions

Indexed keywords

ADIPOCYTOKINE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FIBRIC ACID DERIVATIVE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PITAVASTATIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; RIMONABANT; SIMVASTATIN; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA STENOSIS; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; FIBRINOLYSIS; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION;

EID: 84878626743     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990314     Document Type: Review

References (164)

1. Suchy D, Labuzek K, Stadnicki A, et al. Ezetimibe-a new approach in hypercholesterolemia management. Pharmacol Rep 2011; 63: 1335-48.
2. Manhas A, Farmer JA. Hypolipidemic therapy and cholesterol absorption. Curr Atheroscler Rep 2004; 6: 89-93.
3. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag 2012; 8: 415-27.
4. Filippatos TD, Mikhailidis DP. Lipid-lowering drugs acting at the level of the gastrointestinal tract. Curr Pharm Des 2009; 15: 490-516.
5. Khanderia U, Regal RE, Rubenfire M, et al. The ezetimibe controversy: implications for clinical practice. Ther Adv Cardiovasc Dis 2011; 5: 199-208.
6. Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract 2008; 62: 88-96.
7. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343-56.
8. Ocampo NV, Tafreshi J, Hauschild CL, et al. Cardiovascular medications and risk of cancer. Am J Cardiol 2011; 108: 1045-51.
9. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008; 359: 1357-66.
10. http: //www accessdata fda gov/drugsatfda_docs/nda/ 2002/21445_Zetia cfm 2012
11. Blumenthal RS, Michos ED. The HALTS trial-halting atherosclerosis or halted too early? N Engl J Med 2009; 361: 2178-80.
12. Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med 2008; 358: 1504-7.
13. Katsiki N, Athyros VG, Karagiannis A, et al. Ezetimibe and low density lipoprotein subfractions: an ongoing debate. Curr Med Res Opin 2011; 27: 693-5.
14. Lioudaki E, Ganotakis ES, Mikhailidis DP. Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years. Curr Vasc Pharmacol 2011; 9: 62-86.
15. Paraskevas KI, Veith FJ, Mikhailidis DP. Carotid intima-media thickness and ezetimibe: the end of a misunderstanding? Curr Vasc Pharmacol 2011; 9: 381-4.
16. Toth PP, Maki KC. A Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) Trial: Should ezetimibe move to the "Back of the Line" as a therapy for dyslipidemia? J Clin Lipidol 2008; 2: 313-7.
17. Kastelein JJ, Akdim F, Stroes ES, Z, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43.
18. Simon T, Boutouyrie P, Gompel A, et al. Rationale, design and methods of the CASHMERE study. Fundam Clin Pharmacol 2004; 18: 131-8.
19. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomized, double-blind trial. Lancet 2001; 357: 577-81.
20. Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008; 52: 2198-205.
21. Katsiki N, Lioudaki E, Ganotakis ES, et al. Impact of ezetimibe coadministered with statins on cardiovascular events following acute coronary syndrome: a 3-year population-based retrospective cohort study in taiwan. Clin Ther 2011; 33: 2091.
22. Lin CF, Gau CS, Wu FL, et al. Impact of ezetimibe coadministered with statins on cardiovascular events following acute coronary syndrome: a 3-year population-based retrospective cohort study in Taiwan. Clin Ther 2011; 33: 1120-31.
23. Meaney A, Ceballos G, Asbun J, et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol 2009; 49: 838-47.
24. Avellone G, Di G, V, Guarnotta V, et al. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia. Int Angiol 2010; 29: 514-24.
25. Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23: 2009-26.
26. Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and metaanalysis. Curr Med Res Opin 2011; 27: 1191-210.
27. Holme I, Boman K, Brudi P, et al. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial. Am J Cardiol 2010; 105: 1802-8.
28. Villines TC, Stanek EJ, Devine PJ, T, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010; 55: 2721-6.
29. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet 2011; 377: 2181-92.
30. Chan DC, Watts GF. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opin Pharmacother 2011; 12: 13-30.
31. Guyton JR, Betteridge DJ, Farnier M, et al. Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes. Diab Vasc Dis Res 2011; 8: 160-72.
32. Ruggenenti P, Cattaneo D, Rota S, et al. Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care 2010; 33: 1954-6.
33. Sarigianni M, Katsiki N, Mikhailidis DP. Ezetimibe in diabetes: more than cholesterol lowering? Curr Med Res Opin 2010; 26: 2517-20.
34. Shigematsu E, Yamakawa T, Taguri M, et al. Efficacy of ezetimibe is associated with gender and baseline lipid levels in patients with type 2 diabetes. J Atheroscler Thromb 2012; 19: 846-53.
35. Gazi IF, Daskalopoulou SS, Nair DR, et al. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007; 23: 2183-92.
36. Migdalis I, Efthimiadis A, Pappas S, et al. Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Curr Med Res Opin 2009; 25: 2571-6.
37. Tomassini JE, Mazzone T, Goldberg RB, et al. Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. Diabetes Obes Metab 2009; 11: 855-64.
38. Winkler K, Jacob S, Muller-Schewe T, et al. Ezetimibe alone and in combination lowers the concentration of small, dense lowdensity lipoproteins in type 2 diabetes mellitus. Atherosclerosis 2012; 220: 189-93.
39. Conard S, Bays H, Leiter LA, et al. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab 2010; 12: 210-8.
40. Uemura Y, Watarai M, Ishii H, et al. Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol 2012; 59: 50-6.
41. Nakamura T, Sato E, Amaha M, et al. Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria. J Int Med Res 2012; 40: 798-803.
42. Tamura Y, Murayama T, Minami M, et al. Ezetimibe ameliorates early diabetic nephropathy in db/db mice. J Atheroscler Thromb 2012; 19: 608-18.
43. Almquist T, Jacobson SH, Lins PE, et al P. Effects of lipidlowering treatment on platelet reactivity and platelet-leukocyte aggregation in diabetic patients without and with chronic kidney disease: a randomized trial. Nephrol Dial Transplant 2012; 27: 3540-6.
44. Miyashita Y, Endo K, Saiki A, et al. Effect of ezetimibe monotherapy on lipid metabolism and arterial stiffness assessed by cardioankle vascular index in type 2 diabetic patients. J Atheroscler Thromb 2010; 17: 1070-6.
45. Zhong Y, Wang J, Gu P, et al. Effect of Ezetimibe on Insulin Secretion in db/db Diabetic Mice. Exp Diabetes Res 2012; 2012: 420854.
46. Moutzouri E, Liberopoulos E, Mikhailidis DP, et al. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract 2011; 65: 1141-8.
47. Kater AL, Batista MC, Ferreira SR. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. Metabolism 2010; 59: 921-6.
48. Athyros VG, Mikhailidis DP. Pharmacotherapy: statins and newonset diabetes mellitus-a matter for debate. Nat Rev Endocrinol 2012; 8: 133-4.
49. Athyros VG, Tziomalos K, Karagiannis A, et al. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J 2011; 5: 24-34.
50. Averna M, Missault L, Vaverkova H, et al. Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. Diab Vasc Dis Res 2011; 8: 262-70.
51. Robinson JG, Ballantyne CM, Hsueh W, et al. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity Creactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J Clin Lipidol 2011; 5: 474-82.
52. Bays HE, Shah A, Macdonell G, et al. Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome. Metab Syndr Relat Disord 2011; 9: 135-42.
53. Ansquer JC, Bekaert I, Guy M, et al. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study. Am J Cardiovasc Drugs 2009; 9: 91-101.
54. Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, et al. The effect of statin alone or in combination with ezetimibe on post prandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis 2009; 202: 216-24.
55. Fazio S, Guyton JR, Lin J, et al. Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes Obes Metab 2010; 12: 983-93.
56. Takase H, Dohi Y, Okado T, et al. Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomized controlled study. Eur J Clin Invest 2012; 42: 1287-94.
57. Katsiki N, Athyros VG, Karagiannis A, et al. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011; 9: 698-705.
58. Mikhailidis DP, Lioudaki E, Ganotakis ES. Liver enzymes: potential cardiovascular risk markers? Curr Pharm Des 2011; 17: 3632-43.
59. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-22.
60. Athyros VG, Tziomalos K, Daskalopoulos GN, et al. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med 2011; 43: 167-71.
61. Yoshida M. Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment. Curr Vasc Pharmacol 2011; 9: 121-3.
62. Ahmed MH, Byrne CD. Ezetimibe as a potential treatment for nonalcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation? Drug Discov Today 2010; 15: 590-5.
63. Filippatos TD, Elisaf MS. Role of ezetimibe in non-alcoholic fatty liver disease. World J Hepatol 2011; 3: 265-7.
64. Nozaki Y, Fujita K, Yoneda M, et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 2009; 51: 548-56.
65. Park H, Shima T, Yamaguchi K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 101-7.
66. Abel T, Feher J, Dinya E, et al. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit 2009; 15: MS6-11.
67. Musso G, Cassader M, Gambino R. Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update. Curr Opin Lipidol 2011; 22: 489-96.
68. Hardwick RN, Fisher CD, Street SM, et al. Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug Metab Dispos 2012; 40: 450-60.
69. Upadhyay A, Earley A, Lamont JL, et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and metaanalysis. Ann Intern Med 2012; 157: 251-62.
70. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: 118-27.
71. Athyros VG, Karagiannis A, Ganotakis ES, et al. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011; 27: 1659-68.
72. Athyros VG, Mitsiou EK, Tziomalos K, et al. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. Expert Opin Pharmacother 2010; 11: 723-30.
73. Kalaitzidis RG, Elisaf MS. The role of statins in chronic kidney disease. Am J Nephrol 2011; 34: 195-202.
74. Krane V, Wanner C. Statins, inflammation and kidney disease. Nat Rev Nephrol 2011; 7: 385-97.
75. Athyros VG, Tziomalos K, Karagiannis A, et al. Statins and cardiovascular events in patients with end-stage renal disease on hemodialysis. The AURORA results suggest the need for earlier intervention. Curr Vasc Pharmacol 2009; 7: 264-6.
76. Athyros VG, Katsiki N, Karagiannis A, et al. Stage of chronic kidney disease and severity of coronary heart disease manifestation. Expert Opin Pharmacother 2012; 13: 457-60.
77. Nakamura T, Sato E, Fujiwara N, et al. Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res 2009; 60: 525-8.
78. Nakamura T, Sato E, Fujiwara N, et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res 2010; 61: 58-61.
79. Berthold HK, Krone W, Erdmann E, et al. Lipid lowering in patients with chronic kidney disease: a SHARP turn in the wrong direction? Eur J Cardiovasc Prev Rehabil 2011; 18: 858-61.
80. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007; 45: 645-54.
81. Krucoff MW, Jones WS, Patel MR. Learning to walk before we run: the mechanics of medical intervention for peripheral arterial disease. J Am Coll Cardiol 2011; 58: 1077-9.
82. Rizzo M, Corrado E, Patti AM, et al. Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? Expert Opin Pharmacother 2011; 12: 647-55.
83. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2008; CD003748.
84. West AM, Anderson JD, Meyer CH, et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis 2011; 218: 156-62.
85. Taylor AJ, Villines TC, Stanek EJ. Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe. Eur Heart J 2012.
86. Rizzo M, Battista RG. Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia. Arch Med Sci 2011; 7: 5-7.
87. Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterolassociated actions of ezetimibe: an overview. Expert Opin Ther Targets 2006; 10: 851-66.
88. Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007; 23: 1169-76.
89. Kawagoe Y, Hattori Y, Nakano A, et al. Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients. Endocr J 2011; 58: 171-5.
90. Nakagami H, Osako MK, Takami Y, et al. Vascular protective effects of ezetimibe in ApoE-deficient mice. Atherosclerosis 2009; 203: 51-8.
91. Yunoki K, Nakamura K, Miyoshi T, et al. Impact of hypertriglyceridemia on endothelial dysfunction during statin +/-ezetimibe therapy in patients with coronary heart disease. Am J Cardiol 2011; 108: 333-9.
92. Gounari P, Tousoulis D, Antoniades C, et al. Rosuvastatin but not ezetimibe improves endothelial function in patients with heart failure, by mechanisms independent of lipid lowering. Int J Cardiol 2010; 142: 87-91.
93. Kostapanos MS, Spyrou AT, Tellis CC, et al. Ezetimibe treatment lowers indicators of oxidative stress in hypercholesterolemic subjects with high oxidative stress. Lipids 2011; 46: 341-8.
94. Undas A, Machnik A, Potaczek DP, et al. Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events. J Cardiovasc Pharmacol 2011; 58: 167-72.
95. Yamaoka-Tojo M, Tojo T, Takahira N, et al. Ezetimibe and reactive oxygen species. Curr Vasc Pharmacol 2011; 9: 109-20.
96. Chan DC, Watts GF, Gan SK, et al. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010; 33: 1134-9.
97. Gomez-Garre D, Munoz-Pacheco P, Gonzalez-Rubio ML, et al. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipidlowering effect. Br J Pharmacol 2009; 156: 1218-27.
98. Tamaki N, Ueno H, Morinaga Y, et al. Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 2012; 19: 532-8.
99. Yagi S, Akaike M, Aihara K, et al. Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. J Atheroscler Thromb 2010; 17: 173-80.
100. Berthold HK, Berneis K, Mantzoros CS, et al. Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. Scand Cardiovasc J 2012.
101. Ishibashi T, Takeishi Y. Ezetimibe and vascular inflammation. Curr Vasc Pharmacol 2011; 9: 99-108.
102. Krysiak R, Zmuda W, Okopien B. The effect of ezetimibe and simvastatin on hemostasis in patients with isolated hypercholesterolemia. Fundam Clin Pharmacol 2012; 26: 424-31.
103. Ye Y, Zhao X, Zhai G, et al. Effect of High-Dose Statin Versus Low-Dose Statin Plus Ezetimibe on Endothelial Function: A Metaanalysis of Randomized Trials. J Cardiovasc Pharmacol Ther 2012; 17: 357-65.
104. Dawson JA, Choke E, Loftus IM, et al. A randomized placebocontrolled double-blind trial to evaluate lipid-lowering pharmacotherapy on proteolysis and inflammation in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2011; 41: 28-35.
105. Patel R, Janoudi A, Vedre A, et al. Plaque rupture and thrombosis are reduced by lowering cholesterol levels and crystallization with ezetimibe and are correlated with fluorodeoxyglucose positron emission tomography. Arterioscler Thromb Vasc Biol 2011; 31: 2007-14.
106. Sato K, Nakano K, Katsuki S, et al. Dietary Cholesterol Oxidation Products Accelerate Plaque Destabilization and Rupture Associated with Monocyte Infiltration/Activation via the MCP-1-CCR2 Pathway in Mouse Brachiocephalic Arteries: Therapeutic Effects of Ezetimibe. J Atheroscler Thromb 2012; 19: 986-98.
107. Umemoto T, Subramanian S, Ding Y, et al. Inhibition of intestinal cholesterol absorption decreases atherosclerosis but not adipose tissue inflammation. J Lipid Res 2012; 53: 2380-9.
108. Florentin M, Tselepis AD, Elisaf MS, et al. Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. Curr Vasc Pharmacol 2010; 8: 820-30.
109. Nakou ES, Filippatos TD, Kiortsis DN, et al. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother 2008; 9: 3151-8.
110. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9: 533-71.
111. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011; 9: 531-32.
112. Stojakovic T, de Campo A, Scharnagl H, et al. Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events. Eur J Clin Invest 2010; 40: 187-94.
113. Ose L, Reyes R, Johnson-Levonas AO, et al. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin Ther 2007; 29: 2419-32.
114. Tribble DL, Farnier M, Macdonell G, et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism 2008; 57: 796-801.
115. Berneis K, Rizzo M, Berthold HK, et al. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J 2010; 31: 1633-9.
116. Florentin M, Liberopoulos EN, Moutzouri E, et al. The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin 2011; 27: 685-92.
117. Rizzo M, Rini GB, Spinas GA, et al. The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes? Atherosclerosis 2009; 204: 330-3.
118. Vaverkova H, Farnier M, Averna M, et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy. Cardiovasc Ther 2012; 30: 61-74.
119. Jacobson TA. Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. Mayo Clin Proc 2011; 86: 762-80.
120. Kei AA, Filippatos TD, Tsimihodimos V, et al. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism 2012; 61: 906-21.
121. Bozzetto L, Annuzzi G, Corte GD, et al. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis 2011; 217: 142-8.
122. Kostapanos MS, Elisaf MS, Mikhailidis DP. Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipidemia. J Cardiovasc Pharmacol Ther 2012; 17: 427.
123. Masuda D, Nakagawa-Toyama Y, Nakatani K, et al. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009; 39: 689-98.
124. Hiramitsu S, Miyagishima K, Ishii J, et al. The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. J Cardiol 2012; 60: 395-400.
125. Mihas C, Kolovou GD, Mikhailidis DP, et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: a metaanalysis. Curr Vasc Pharmacol 2011; 9: 271-80.
126. Kolovou GD, Mikhailidis DP, Nordestgaard BG, Bilianou H, Panotopoulos G. Definition of postprandial lipaemia. Curr Vasc Pharmacol 2011; 9: 292-301.
127. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011; 9: 258-70.
128. Kurobe H, Aihara K, Higashida M, et al. Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress. J Atheroscler Thromb 2011; 18: 1080-9.
129. Maki-Petaja KM, Booth AD, Hall FC, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007; 50: 852-8.
130. Efrati S, Averbukh M, Dishy V, et al. The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur J Clin Pharmacol 2007; 63: 113-21.
131. Doonan RJ, Scheffler P, Lalli M, et al. Increased arterial stiffness in obstructive sleep apnea: a systematic review. Hypertens Res 2011; 34: 23-32.
132. Seifalian AM, Filippatos TD, Joshi J, et al. Obesity and arterial compliance alterations. Curr Vasc Pharmacol 2010; 8: 155-68.
133. Ugurlucan M, Erer D, Kalko Y, et al. Aortic stiffness in diabetes mellitus-association with glutamine and heat shock protein 70 expression: a pilot study based on an experimental rodent model. Expert Opin Ther Targets 2009; 13: 267-74.
134. Katsiki N, Koumaras C, Athyros VG, et al. Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk. Angiology 2012; 63: 9-11.
135. Koumaras C, Tzimou M, Stavrinou E, et al. Role of antihypertensive drugs in arterial 'de-stiffening' and central pulsatile hemodynamics. Am J Cardiovasc Drugs 2012; 12: 143-56.
136. Tziomalos K, Athyros VG, Karagiannis A, et al. Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets 2007; 11: 1143-60.
137. Florentin M, Liberopoulos EN, Tellis CC, et al. Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study. Angiology 2010; 61: 365-71.
138. Gouni-Berthold I, Berthold HK, Chamberland JP, et al. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol (Oxf) 2008; 68: 536-41.
139. Gupta M, Szmitko PE, Tsigoulis M, et al. Effects of ezetimibe addon to statin therapy on adipokine production in patients with meta bolic syndrome and stable vascular disease. J Cardiovasc Pharmacol 2010; 56: 241-5.
140. Perelas A, Tsoulkani A, Perrea D. Effects of lipid-lowering drugs on adiponectin. Curr Vasc Pharmacol 2010; 8: 836-48.
141. Ason B, Tep S, Davis HR, Jr., et al. Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. J Lipid Res 2011; 52: 679-87.
142. Lagace TA, Curtis DE, Garuti R, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006; 116: 2995-3005.
143. Blagden MD, Chipperfield R. Efficacy and safety of ezetimibe coadministered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin 2007; 23: 767-75.
144. Leiter LA, Bays H, Conard S, et al. Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin. Int J Clin Pract 2010; 64: 1765-72.
145. McCormack T, Harvey P, Gaunt R, et al. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomized controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. Int J Clin Pract 2010; 64: 1052-61.
146. Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005; 21: 959-69.
147. Descamps OS, De Sutter J, Guillaume M, et al. Where does the interplay between cholesterol absorption and synthesis in the context of statin and/or ezetimibe treatment stand today? Atherosclerosis 2011; 217: 308-21.
148. Thongtang N, Lin J, Schaefer EJ, et al. Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients. Atherosclerosis 2012; 225: 388-96.
149. Lioudaki E, Ganotakis ES, Mikhailidis DP. Lipid lowering drugs and gallstones: a therapeutic option? Curr Pharm Des 2011; 17: 3622-31.
150. Abramson BL, Benlian P, Hanson ME, et al. Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients. Lipids Health Dis 2011; 10: 146.
151. Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 2003; 19: 155-168.
152. Athyros VG, Tziomalos K, Karagiannis A, et al. Statin-fibrate combination for mixed dyslipidaemia: a limited option? Curr Med Res Opin 2010; 26: 2137-40.
153. Agouridis AP, Filippatos TD, Derdemezis CS, et al. Combination of fenofibrate with non-statin drug regimens. Curr Pharm Des 2010; 16: 3401-16.
154. Farnier M, Retterstol K, Steinmetz A, et al. Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease. Diab Vasc Dis Res 2012; 9: 205-15.
155. Jones PH, Goldberg AC, Knapp HR, et al. Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. Am Heart J 2010; 160: 759-66.
156. Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf 2011; 10: 373-87.
157. Kumar SS, Lahey KA, Day A, et al. Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. Lipids Health Dis 2009; 8: 56.
158. Tziomalos K, Athyros VG, Karagiannis A, et al. Management of statin-intolerant high-risk patients. Curr Vasc Pharmacol 2010; 8: 632-7.
159. Reddy KJ, Singh M, Batsell RR, et al. Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use. J Clin Hypertens (Greenwich) 2009; 11: 766-8.
160. Athyros VG, Tziomalos K, Kakafika AI, et al. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008; 101: 483-5.
161. Derosa G, D'Angelo A, Franzetti IG, et al. Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. J Clin Pharm Ther 2009; 34: 267-76.
162. Florentin M, Kostapanos MS, Nakou ES, et al. Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia. J Cardiovasc Pharmacol Ther 2009; 14: 274-82.
163. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008; 156: 826-32.
164. Gouni-Berthold I, Mikhailidis DP, Rizzo M. Clinical benefits of ezetimibe use: is absence of proof, proof of absence? Expert Opin Pharmacother 2012; 13: 1985-8.